Y. Barenholz
Molecular Biology · 2001–2012
A researcher in the Science corpus: 3 papers; trusts 4 researchers and is trusted by 28 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 6 citations into it; #1,250 of 17,773 by trust here, #6,095 by citations
- Cancer Research — 5 citations into it
Whom Y. Barenholz trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Y. Barenholz overall
- Upendra Bulbake
- Phatsapong Yingchoncharoen
- Peng Liu
- Camilla Hald Albertsen
- Sindhu Doppalapudi
- D. Kalinowski
- Guiliang Chen
- J. Kulkarni
- A. Anselmo
- S. Mitragotri
Papers from Y. Barenholz's perspective
Ordered by how strongly the researchers Y. Barenholz trusts endorse each paper. Same corpus, a different order for every researcher.
- Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors (Proceedings of the National Academy of Sciences of the United States of America)
- Transport of molecules across tumor vasculature (Cancer Metastasis Review)
- Liposome application: problems and prospects
- Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
- Pathology: Cancer cells compress intratumour vessels (Nature)
- Molecular mechanisms of drug resistance (Journal of Pathology)
- Recent advances with liposomes as pharmaceutical carriers (Nature reviews. Drug discovery)
- Collagens--structure, function, and biosynthesis. (Advanced Drug Delivery Reviews)
- Nanoparticle therapeutics: an emerging treatment modality for cancer (Nature reviews. Drug discovery)
- Role of extracellular matrix assembly in interstitial transport in solid tumors. (Cancer Research)
Their papers
- Doxil®--the first FDA-approved nano-drug: lessons learned. (2012) — 4,234 citations
- Liposome application: problems and prospects (2001) — 596 citations
- Pharmacokinetics of Pegylated Liposomal Doxorubicin (2003) — 1,213 citations